Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate the Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

Trial Profile

A Study to Evaluate the Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NYX-783 (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Therapeutic Use
  • Sponsors Aptinyx
  • Most Recent Events

    • 12 Aug 2019 According to an Aptinyx media release, completion and reporting top-line data from this study is expected in 2H2020.
    • 14 May 2019 According to an Aptinyx media release, trial completion expected in 1H 2020.
    • 19 Feb 2019 According to an Aptinyx media release, first patient has been dosed in the study. The company expects to report data from this study in the first half of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top